Kridin K, Schonmann Y, Damiani G, et al. - This study sought to evaluate the risk of COVID-19 infection, COVID-19-associated hospitalization, and mortality among Israeli patients with psoriasis treated by TNFi relative to other systemic agents. Researchers performed a population-based cohort study to compare psoriasis patients treated by TNFi (n = 1,943), with those treated by methotrexate (n = 1,929), ustekinumab (n = 348), and acitretin (n = 1892) regarding COVID-19 outcomes. Uni- and multi-variate Cox regression analyses were used to evaluate the risk of investigated outcomes. The observations substantiate the continuation of TNFi treatment during the pandemic. As per the results, TNFi may be positively considered in patients with moderate-to-severe psoriasis warranting systemic treatment during the pandemic.